Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT toxicity in patients with chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemia

A. Shimoni, M. Leiba, M. Schleuning, G. Martineau, M. Renaud, M. Koren-Michowitz, E. Ribakovski, P. le Coutre, R. Arnold, F. Guilhot, A. Nagler

Research output: Contribution to journalLetterpeer-review

35 Scopus citations

Fingerprint

Dive into the research topics of 'Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT toxicity in patients with chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences